If you said Health Secretary Francisco Duque 3rd, you guessed right.
According to Malacañang insiders, Duterteâs workmates are wondering why President Rodrigo âDigongâ Duterte (PRRD) keeps on defending him despite his many lapses.
One Cabinet member said if he had his way, he would bash Duqueâs head for bringing shame to PRRDâs official family.
Duqueâs latest caper was botching a government deal with US pharmaceutical firm Pfizer to supply the Philippines with 10 million doses of the anti-Covid vaccine.
As Foreign Secretary Teodoro âTeddyboyâ Locsin Jr. put it, Duque âdropped the ballâ on the deal, which Locsin and Philippine Ambassador to the US Jose Manuel âBabesâ Romualdez worked hard to get.
DOH maintains support for Duque despite resignation calls — Vergeire
inquirer.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from inquirer.net Daily Mail and Mail on Sunday newspapers.
Caveat on confidentiality agreements
inquirer.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from inquirer.net Daily Mail and Mail on Sunday newspapers.
PH to get 30M doses of Indian-made Novavax
inquirer.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from inquirer.net Daily Mail and Mail on Sunday newspapers.
(JANSEN ROMERO / FILE PHOTO / MANILA BULLETIN)
In an interview aired over CNN Philippines, Foreign Affairs Secretary Teodoro Locsin Jr. revealed Monday the country may secure the deal before year ends, citing that the information came from the Serum Institute of India, currently the world’s largest vaccine producer.
“Thirty million dosages of the Indian-made Novavax vaccines are assured possibly with no cash advance which will be available by July 2021,” he said.
“The term sheet might be signed before the year ends,” he added.
Last September, American vaccine development company Novavax Inc. announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two billion doses annually.